Outcome Prediction

At Radiomics we want to play a key role in the upcoming precision medicine landscape, where treatments are directly based on the individual patient’s characteristics rather than on standardized protocols designed for groups of patients having a similar diagnostic range.

We successfully achieved to prospectively validate our predictive 2-year survival signature based on CT scans for NSCLC patients treated with chemoradiotherapy and are currently entering the final phase before obtaining class 2 MDR regulatory clearance.
Radiomics outcome prediction